Young-Sun Sohn
Corporate Officer/Principal at Catholic University of Korea
Profile
Young-Sun Sohn is a Professor at Catholic University of Korea.
Previously, he worked as the Chief Executive Officer at Abxign, Inc., Director-Biotechnology Research Center at Daewoong Pharmaceutical Co., Ltd., and Principal Scientist at CJ Corp.
Young-Sun Sohn active positions
Companies | Position | Start |
---|---|---|
Catholic University of Korea | Corporate Officer/Principal | 15/09/2011 |
Former positions of Young-Sun Sohn
Companies | Position | End |
---|---|---|
Abxign, Inc.
Abxign, Inc. Pharmaceuticals: MajorHealth Technology Abxign, Inc. was established in January 2008 and is located in Samsung Cancer Research building in Seoul National University. Abxign focused on the discovery and development of antibody therapeutics where by first or best-in-class therapies are introduced in large and growing markets with quality partners. Abxign has accumulated therapeutic antibody development technology and experience for many years and maintains relationships with domestic and foreign pharmaceutical companies specialized for each part of the development of antibody therapy. Based on these Abxign's network and technology, it will release the excellent antibodies in the world pharmaceutical market and extend the human life and contribute to improving the quality of life. | President | 25/07/2013 |
CJ CORPORATION | Chief Tech/Sci/R&D Officer | - |
DAEWOONG PHARMACEUTICAL CO., LTD | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
CJ CORPORATION | Consumer Non-Durables |
DAEWOONG PHARMACEUTICAL CO., LTD | Health Technology |
Private companies | 1 |
---|---|
Abxign, Inc.
Abxign, Inc. Pharmaceuticals: MajorHealth Technology Abxign, Inc. was established in January 2008 and is located in Samsung Cancer Research building in Seoul National University. Abxign focused on the discovery and development of antibody therapeutics where by first or best-in-class therapies are introduced in large and growing markets with quality partners. Abxign has accumulated therapeutic antibody development technology and experience for many years and maintains relationships with domestic and foreign pharmaceutical companies specialized for each part of the development of antibody therapy. Based on these Abxign's network and technology, it will release the excellent antibodies in the world pharmaceutical market and extend the human life and contribute to improving the quality of life. | Health Technology |
- Stock Market
- Insiders
- Young-Sun Sohn